SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 1

An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis

Müçteba Enes YAYLA
Ufuk İLGEN
Nurşen DÜZGÜN
Pages
10–15
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a significant association betweenantitopoisomerase I positivity and interstitial lung disease (P < 0.001), and interestingly there was also a significant association betweenanti-SS-A 52 positivity and the presence of digital ulcers in patients with SSc.Conclusion: Our data show that anti-RNAP III in SSc patients was low in frequency in a Turkish population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: We aimed to investigate the prevalence of anti-RNA polymerase (RNAP) III and other autoantibodies in a group ofTurkish patients with systemic sclerosis (SSc) and their relation with clinical features.Materials and methods: The prevalence of anti-RNAP III and other autoantibodies was analyzed in 93 patients with SSc and controlgroups including 86 patients with systemic lupus erythematosus (SLE) and 65 healthy subjects, respectively.
📊
Key Findings & Data:Their relationship withdiseases findings was assessed in a cross-sectional manner.Results: Prevalences of anti-RNAP III were 2/93 (2.2%) in SSc, 1/86 (1.2%) in SLE, and 1/65 (1.5%) in the healthy group and there was nodifference among groups (P > 0.999).
💡
Conclusion & Impact:There was a significant association betweenantitopoisomerase I positivity and interstitial lung disease (P < 0.001), and interestingly there was also a significant association betweenanti-SS-A 52 positivity and the presence of digital ulcers in patients with SSc.Conclusion: Our data show that anti-RNAP III in SSc patients was low in frequency in a Turkish population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: We aimed to investigate the prevalence of anti-RNA polymerase (RNAP) III and other autoantibodies in a group ofTurkish patients with systemic sclerosis (SSc) and their relation with clinical features.Materials and methods: The prevalence of anti-RNAP III and other autoantibodies was analyzed in 93 patients with SSc and controlgroups including 86 patients with systemic lupus erythematosus (SLE) and 65 healthy subjects, respectively. Their relationship withdiseases findings was assessed in a cross-sectional manner.Results: Prevalences of anti-RNAP III were 2/93 (2.2%) in SSc, 1/86 (1.2%) in SLE, and 1/65 (1.5%) in the healthy group and there was nodifference among groups (P > 0.999). Anti-Sm was significantly more common in SLE patients (P < 0.001), whereas antitopoisomerase Iand anticentromere protein B were significantly more common in SSc patients (P < 0.001). There was a significant association betweenantitopoisomerase I positivity and interstitial lung disease (P < 0.001), and interestingly there was also a significant association betweenanti-SS-A 52 positivity and the presence of digital ulcers in patients with SSc.Conclusion: Our data show that anti-RNAP III in SSc patients was low in frequency in a Turkish population.

🔖

Cite This Article

YAYLA, M. E., İLGEN, U., DÜZGÜN, N. (2022). An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 1, 10–15. https://ajindex.com/articles/610201

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheumatol 2003; 48: 2246-2255.
  2. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler M, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheumatol 1980; 23: 617-625.
  3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger T Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 2008; 158: 19-28.
  4. Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, Hayem G, Palazzo E, Chollet-Martin S, Kahan A et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010; 37: 125-130.
  5. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA. Enzyme-linked immunosorbent assay for detection of Anti–RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheumatol 2005; 52: 2425-2432.
  6. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007; 34: 1528-1534.
  7. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 2009; 48: 1570-1574.
  8. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthrit Care Res 2003; 49: 399-412.
  9. Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE et al. 2013 classification criteria for systemic sclerosis: an American college of rheu